Pfizer To Appeal Lipitor Patents In Norway

Law360 (May 29, 2007, 12:00 AM EDT) -- Pfizer Inc. plans to appeal a Norwegian appeals court decision that deemed its Lipitor patents invalid or uninfringed by Ranbaxy's generic version, the company said.

The Norwegian Supreme Court has yet to decide whether it will hear the appeal.

The Borgarting Court of Appeal in Oslo ruled Tuesday that three patents covering the cholesterol-lowering drug would not be infringed by Ranbaxy's generic and that one other patent was invalid.

“We are disappointed by the court’s ruling,” said Allen Waxman, general counsel for the pharmaceutical giant. “But...
To view the full article, register now.